Amyloid Precursor Protein ELISA Test

Amyloid Precursor Protein ELISA Test

Introduction of Amyloid Precursor Protein

The essential human body molecule known as amyloid precursor protein (APP) is important for the onset of Alzheimer's disease. This naturally occurring protein can be found in many tissues, including the brain. Though its precise purpose is still unclear, it is thought to play a significant part in neuronal growth, repair, and cell-to-cell communication.

The amyloid precursor protein (APP) is a transmembrane protein that can undergo a series of proteolytic cleavage by secretase enzymes.Figure 1. The amyloid precursor protein (APP) is a transmembrane protein that can undergo a series of proteolytic cleavage by secretase enzymes.( Patterson C, et al.; 2008)

APP is particularly associated with the formation of amyloid plaques, which are one of the hallmarks of Alzheimer's disease. These plaques consist of abnormal clumps of proteins called beta-amyloid, which accumulate in the brain and disrupt normal neuronal function. It is the accumulation of these plaques that leads to the progressive decline in cognitive abilities seen in Alzheimer's patients.

The production and processing of APP are complex processes. APP is initially synthesized as a larger protein molecule that undergoes various modifications and cleavages. One of the key steps is the cleavage of APP by specific enzymes, resulting in the release of different fragments, including beta-amyloid. In healthy individuals, these fragments are cleared efficiently, preventing the accumulation of amyloid plaques. However, in Alzheimer's disease, there is an imbalance between production and clearance, leading to plaque buildup.


The Amyloid Precursor Protein (APP) ELISA test is a diagnostic tool used to measure the levels of APP in biological samples, particularly in research related to Alzheimer's disease. ELISA stands for Enzyme-Linked Immunosorbent Assay and is a widely used laboratory technique for detecting and quantifying specific proteins.

The Process of APP ELISA Test

The APP ELISA test utilizes the principles of immunoassay to detect and quantify APP in a sample. The test involves several steps, starting with the coating of a microplate with specific antibodies that bind to APP. The sample, which can be cerebrospinal fluid, blood, or brain tissue extract, is then added to the microplate, allowing any APP present in the sample to bind to the immobilized antibodies.

After incubation, the microplate is washed to remove any unbound substances. A secondary antibody, labeled with an enzyme, is then added. This secondary antibody recognizes and binds to a different region of the APP molecule, allowing for the formation of a sandwich-like complex: the immobilized antibody on the plate, the APP molecule, and the labeled secondary antibody.

Following another round of washing to remove any excess secondary antibody, a substrate specific to the enzyme label is added. The enzyme catalyzes a reaction that produces a detectable signal, usually a color change. The intensity of the signal is proportional to the amount of APP present in the sample.

By comparing the signal obtained from the sample to a standard curve generated using known concentrations of APP, researchers can determine the precise amount of APP in the sample. This quantitative data is invaluable in understanding the levels of APP in different biological samples and their correlation with various conditions, such as Alzheimer's disease.


The APP ELISA test has proven to be a valuable tool in Alzheimer's disease research, enabling researchers to investigate the relationship between APP levels, disease progression, and potential therapeutic interventions. It has also been used in clinical studies to assess the efficacy of drugs targeting APP processing and clearance.

In conclusion, the APP ELISA test is a powerful laboratory technique used to quantify the levels of APP in biological samples. This test plays a crucial role in advancing our understanding of Alzheimer's disease and other related neurological conditions, facilitating research and the development of potential treatments.


  1. Patterson C, et al.; Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ. 2008,178(5):548-56.
  2. O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci. 2011, 34:185-204.
  3. Wilkins HM, Swerdlow RH. Amyloid precursor protein processing and bioenergetics. Brain Res Bull. 2017, 133:71-79.
The service is for research only, not for clinical use.
Online Inquiry